Mast Cell Activation Syndrome
Why It Matters
Greater recognition of MCAS is important for clinicians and health systems because its protean symptoms drive diagnostic uncertainty, influence medication use and emergency care, and can reduce morbidity when targeted therapies are applied promptly.
Summary
Mast cell activation syndrome (MCAS) is a spectrum of disorders in which mast cells — immune sentinels located in skin, lungs and gut — inappropriately release mediators like histamine and leukotrienes, producing variable, multisystem symptoms. Triggers can be benign (foods, scents, temperature, stress) and episodes may mimic anaphylaxis; underlying causes include altered mast‑cell regulation, genetics, chronic inflammation or autoimmune disease. Diagnosis relies on three criteria: recurrent multi‑system symptoms, biochemical evidence of mediator release (eg, elevated tryptase during symptoms) and clinical response to mediator‑directed therapy. Management centers on H1/H2 antihistamines, leukotriene inhibitors, mast‑cell stabilizers and epinephrine for severe reactions.
Comments
Want to join the conversation?
Loading comments...